cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25934/pr00012318
title: A Randomized Double-blind Phase III Study of RAD001 10 mg/d Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumor (NET)

description: The purpose of this study was to evaluate progression free survival in those participants assigned everolimus 10 mg/day plus Best Supportive Care versus those assigned to placebo plus Best Supportive Care in Advanced Neuroendocrine Tumors of pancreatic origin.
DOI: 10.25934/pr00012319
title: A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis

description: This was a randomized, double-blind, active controlled, multicenter, parallel-group study evaluating secukinumab monotherapy and adalimumab monotherapy in approximately 850 patients with active psoriatic arthritis (PsA) who are naïve to biologic therapy and are intolerant or having inadequate response to conventional disease modifying anti-rheumatic drugs (also known as non-biologic DMARDs).
DOI: 10.13130/rd_unimi/cbrkhv/vlko74
title: Gennaio_1927_Pagina_062.jpg

description: Bulletin of 1927/01/16
DOI: 10.13130/rd_unimi/xu1sm0/mjkqe4
title: Giugno_1893_Pagina_047.jpg

description: Bulletin of 1893/06/12
DOI: 10.25934/pr00012320
title: A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

description: This was a Phase II, multicenter, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib administered as a single agent and in combination with trametinib in stage IV disease to subjects with BRAF mutant advanced non-small cell lung cancer. Central confirmation testing for the BRAF V600E mutation was performed and a sufficient number of subjects were enrolled with the intent of having at least 125 centrally confirmed subjects among the three cohorts.
DOI: 10.13130/rd_unimi/6np0bt/xuxjjp
title: Giugno_1894_Pagina_031.jpg

description: Bulletin of 1894/06/08
DOI: 10.13130/rd_unimi/awv4gb/kp3swx
title: Giugno_1896_Pagina_025.jpg

description: Bulletin of 1896/06/07
DOI: 10.13130/rd_unimi/v8alup/pafcyc
title: Giugno_1891_Pagina_069.jpg

description: Bulletin of 1891/06/18
DOI: 10.25934/pr00012321
title: A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

description: This is a two-arm, open-label, randomized Phase III study comparing single agent GSK1120212 to chemotherapy (either dacarbazine or paclitaxel) in subjects with Stage IIIc or Stage IV malignant cutaneous melanoma. All subjects must have a BRAF mutation-positive tumour sample. Subjects who have received up to one prior regimen of chemotherapy in the advanced or metastatic melanoma setting will be enrolled into the study. Subjects with any prior BRAF or MEK inhibitor use will be excluded. Approximately 297 subjects will be enrolled with 2:1 randomization (198 subjects into the GSK1120212 arm and 99 subjects into the chemotherapy arm). The primary endpoint for the statistical analysis will be a comparison of progression free survival for subjects receiving GSK1120212 compared to chemotherapy. Subjects who have progression on chemotherapy will be offered the option to receive GSK1120212.
DOI: 10.13130/rd_unimi/gsbgp1/f0f5lt
title: Giugno_1889_Pagina_088.jpg

description: Bulletin of 1889/06/22
DOI: 10.13130/rd_unimi/jvs9pt/h38lfa
title: Giugno_1892_Pagina_046.jpg

description: Bulletin of 1892/06/12
DOI: 10.13130/rd_unimi/nsvbhr/3fau8c
title: Giugno_1890_Pagina_073.jpg

description: Bulletin of 1890/06/19
DOI: 10.13130/rd_unimi/rjrjox/fgepds
title: Luglio_1895_Pagina_110.jpg

description: Bulletin of 1895/07/28
DOI: 10.25934/pr00012322
title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis

description: This study will assess the efficacy and safety of secukinumab compared to placebo in adult patients who have moderate to severe scalp psoriasis that is poorly controlled by current psoriasis treatments.
DOI: 10.13130/rd_unimi/awv4gb/skziwp
title: Giugno_1896_Pagina_026.jpg

description: Bulletin of 1896/06/07
DOI: 10.13130/rd_unimi/xu1sm0/i5yyrk
title: Giugno_1893_Pagina_048.jpg

description: Bulletin of 1893/06/12
DOI: 10.25934/pr00012323
title: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With Vildagliptin in Type 2 Diabetes Mellitus Patients ≥ 70 Years (Drug-naive or Inadequately Controlled on Oral Agents)

description: This study will evaluate the efficacy and safety of vildagliptin 50 mg bid in elderly patients with Type 2 Diabetes Mellitus (T2DM).
DOI: 10.13130/rd_unimi/6np0bt/rl31cd
title: Giugno_1894_Pagina_032.jpg

description: Bulletin of 1894/06/08
DOI: 10.13130/rd_unimi/cbrkhv/qrnbug
title: Gennaio_1927_Pagina_063.jpg

description: Bulletin of 1927/01/16
DOI: 10.13130/rd_unimi/v8alup/j3xege
title: Giugno_1891_Pagina_070.jpg

description: Bulletin of 1891/06/18
DOI: 10.25934/pr00012324
title: A 24-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus.

description: To assess the efficacy and safety of vildagliptin add-on therapy to reduce HbA1c in patients with T2DM inadequately controlled by insulin, with or without concurrent metformin therapy.
DOI: 10.13130/rd_unimi/gsbgp1/iw4k3e
title: Giugno_1889_Pagina_089.jpg

description: Bulletin of 1889/06/23
DOI: 10.13130/rd_unimi/jvs9pt/ftrt6b
title: Giugno_1892_Pagina_047.jpg

description: Bulletin of 1892/06/12
DOI: 10.13130/rd_unimi/rjrjox/3bgsna
title: Luglio_1895_Pagina_100.jpg

description: Bulletin of 1895/07/25
DOI: 10.25934/pr00012325
title: A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of 52 Weeks Treatment With Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

description: This study will assess the effect of vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure (NYHA Class I-III). Effect on HbA1c and overall safety and tolerability will also be assessed.
DOI: 10.25934/pr00012326
title: Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

description: This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as add-on therapy to metformin
DOI: 10.13130/rd_unimi/awv4gb/nphqaj
title: Giugno_1896_Pagina_027.jpg

description: Bulletin of 1896/06/07
DOI: 10.13130/rd_unimi/cbrkhv/jdknpp
title: Gennaio_1927_Pagina_064.jpg

description: Bulletin of 1927/01/16
DOI: 10.13130/rd_unimi/nsvbhr/vbuqiv
title: Giugno_1890_Pagina_074.jpg

description: Bulletin of 1890/06/19
DOI: 10.13130/rd_unimi/v8alup/i64yzj
title: Giugno_1891_Pagina_071.jpg

description: Bulletin of 1891/06/18
DOI: 10.25934/pr00012327
title: A 28 Week Extension to a 24 Week Multi-center, Randomized, Double-blind Clinical Trial to Evaluate the Safety and Tolerability of Vildagliptin (50 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency

description: This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) when used in patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal insufficiency
DOI: 10.13130/rd_unimi/rjrjox/6vutjd
title: Luglio_1895_Pagina_112.jpg

description: Bulletin of 1895/07/28
DOI: 10.13130/rd_unimi/xu1sm0/dnmkxt
title: Giugno_1893_Pagina_049.jpg

description: Bulletin of 1893/06/13
DOI: 10.25934/pr00012328
title: A Multi-center, Randomized, Double-blind Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment With (50 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency

description: This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) when used in patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal insufficiency.
DOI: 10.13130/rd_unimi/6np0bt/djnwn6
title: Giugno_1894_Pagina_033.jpg

description: Bulletin of 1894/06/09
DOI: 10.13130/rd_unimi/gsbgp1/indpyq
title: Giugno_1889_Pagina_090.jpg

description: Bulletin of 1889/06/23
DOI: 10.25574/03201
title: Chandra X-ray Observatory ObsId 03201

description: GAS DENSITY DISCONTINUITIES IN MERGING CLUSTERS
DOI: 10.25934/pr00012329
title: A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 100 mg qd or Metformin 1500 mg Daily in Elderly Drug Naive Patients With Type 2 Diabetes

description: This study is designed to demonstrate the efficacy and safety of vildagliptin compared to metformin in elderly drug naive patients with type 2 diabetes
DOI: 10.13130/rd_unimi/awv4gb/wq9n6w
title: Giugno_1896_Pagina_028.jpg

description: Bulletin of 1896/06/07
DOI: 10.13130/rd_unimi/nsvbhr/0ltswv
title: Giugno_1890_Pagina_075.jpg

description: Bulletin of 1890/06/19
DOI: 10.13130/rd_unimi/v8alup/by0aly
title: Giugno_1891_Pagina_072.jpg

description: Bulletin of 1891/06/18
DOI: 10.25934/pr00012330
title: Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

description: Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of glimepiride in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone.
DOI: 10.13130/rd_unimi/cbrkhv/wug7nz
title: Gennaio_1927_Pagina_065.jpg

description: Bulletin of 1927/01/17
DOI: 10.13130/rd_unimi/jvs9pt/ykjeuo
title: Giugno_1892_Pagina_048.jpg

description: Bulletin of 1892/06/12
DOI: 10.25574/03202
title: Chandra X-ray Observatory ObsId 03202

description: GAS DENSITY DISCONTINUITIES IN MERGING CLUSTERS
DOI: 10.25934/pr00012331
title: Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes

description: This study is not being conducted in the United States. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to gliclazide in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar.
DOI: 10.34740/kaggle/dsv/14179122
title: Peer-to-Peer Boliviano (BOB) Exchange Data
DOI: 10.13130/rd_unimi/6np0bt/n8ycgo
title: Giugno_1894_Pagina_034.jpg

description: Bulletin of 1894/06/09
DOI: 10.13130/rd_unimi/gsbgp1/ixx0td
title: Giugno_1889_Pagina_091.jpg

description: Bulletin of 1889/06/23
DOI: 10.13130/rd_unimi/rjrjox/bfb4hj
title: Luglio_1895_Pagina_102.jpg

description: Bulletin of 1895/07/26
DOI: 10.13130/rd_unimi/xu1sm0/rnfozp
title: Giugno_1893_Pagina_050.jpg

description: Bulletin of 1893/06/13
DOI: 10.25934/pr00012332
title: Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes

description: Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of two doses of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to glimepiride in people with type 2 diabetes not at target blood glucose levels on a sulfonylurea alone.
DOI: 10.13130/rd_unimi/jvs9pt/kuwxpf
title: Giugno_1892_Pagina_049.jpg

description: Bulletin of 1892/06/13
DOI: 10.13130/rd_unimi/v8alup/jdkx3x
title: Giugno_1891_Pagina_073.jpg

description: Bulletin of 1891/06/19
DOI: 10.25934/pr00012333
title: Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

description: The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to rosiglitazone in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar.
DOI: 10.13130/rd_unimi/awv4gb/1tjukr
title: Giugno_1896_Pagina_029.jpg

description: Bulletin of 1896/06/08
DOI: 10.13130/rd_unimi/cbrkhv/2tnvt4
title: Gennaio_1927_Pagina_066.jpg

description: Bulletin of 1927/01/17
DOI: 10.13130/rd_unimi/nsvbhr/xyyoqx
title: Giugno_1890_Pagina_076.jpg

description: Bulletin of 1890/06/19
DOI: 10.25574/03203
title: Chandra X-ray Observatory ObsId 03203

description: ABELL 168, A RARE MERGER WITH THE SIMPLEST GEOMETRY
DOI: 10.25934/pr00012334
title: Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes

description: The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to metformin in lowering overall blood glucose levels in people with type 2 diabetes who have not been previously treated with drug therapy to lower their blood sugar.
DOI: 10.25934/pr00012335
title: Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes

description: This study is not being conducted in the United States. Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to that of gliclazide in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone.
DOI: 10.13130/rd_unimi/gsbgp1/ddbnwe
title: Giugno_1889_Pagina_092.jpg

description: Bulletin of 1889/06/23
DOI: 10.13130/rd_unimi/rjrjox/0gym00
title: Luglio_1895_Pagina_117.jpg

description: Bulletin of 1895/07/30
DOI: 10.13130/rd_unimi/xu1sm0/vjhbry
title: Giugno_1893_Pagina_051.jpg

description: Bulletin of 1893/06/13
DOI: 10.25934/pr00012336
title: A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.

description: The purpose of this study was to test whether two investigational drugs called CAD106 and CNP520, administered separately, could slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype.
DOI: 10.13130/rd_unimi/6np0bt/l2jctg
title: Giugno_1894_Pagina_035.jpg

description: Bulletin of 1894/06/09
DOI: 10.13130/rd_unimi/v8alup/nkgtwg
title: Giugno_1891_Pagina_074.jpg

description: Bulletin of 1891/06/19
DOI: 10.25934/pr00012337
title: A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).

description: The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.
DOI: 10.13130/rd_unimi/cbrkhv/zwvtio
title: Gennaio_1927_Pagina_067.jpg

description: Bulletin of 1927/01/17
DOI: 10.13130/rd_unimi/jvs9pt/uvxjdu
title: Giugno_1892_Pagina_050.jpg

description: Bulletin of 1892/06/13
DOI: 10.13130/rd_unimi/nsvbhr/4kswm9
title: Giugno_1890_Pagina_077.jpg

description: Bulletin of 1890/06/20
DOI: 10.13130/rd_unimi/xu1sm0/lk3k6h
title: Giugno_1893_Pagina_052.jpg

description: Bulletin of 1893/06/13
DOI: 10.25934/pr00012338
title: A Phase III, Randomized, Double-blind, Placebo Controlled Multi-center Study of Subcutaneous Secukinumab (150 mg and 300 mg) in Prefilled Syringe to Demonstrate Efficacy (Including Inhibition of Structural Damage), Safety, and Tolerability up to 2 Years in Subjects With Active Psoriatic Arthritis (FUTURE 5)

description: The purpose of this study was to demonstrate efficacy including effect on inhibition of progression of structural damage, safety and tolerability up to 2 years with primary focus at Week 16 (week 24 for structural damage), to support the use of secukinumab pre-filled syringe (PFS) by subcutaneous (s.c.) self-administration with or without loading regimen in subjects with active Psoriatic Arthritis (PsA) despite current or previous NSAID, DMARD therapy and/or previous anti-TNFα therapy. Long term efficacy up to 2 years was based on signs and symptoms of joint/bone structure preservation (X-ray) and improvement in physical function measured by Health Assessment Questionnaire - Disability Index (HAQ-DI©), as well as skin and nail improvement for psoriasis signs.
DOI: 10.5281/zenodo.17650402
title: Dataset of the article "Urban airborne allergenic pollen shows highly local patterns driven by public green spaces".

description: Raw nrITS2 metabarcoding reads used for analyses in this article
DOI: 10.13130/rd_unimi/awv4gb/uoyjev
title: Giugno_1896_Pagina_030.jpg

description: Bulletin of 1896/06/08
DOI: 10.13130/rd_unimi/gsbgp1/volxwp
title: Giugno_1889_Pagina_093.jpg

description: Bulletin of 1889/06/24
DOI: 10.13130/rd_unimi/rjrjox/iedhqn
title: Luglio_1895_Pagina_119.jpg

description: Bulletin of 1895/07/30
DOI: 10.25574/03204
title: Chandra X-ray Observatory ObsId 03204

description: ABELL 168, A RARE MERGER WITH THE SIMPLEST GEOMETRY
DOI: 10.25934/pr00012339
title: Secukinumab In Patients With Moderate to Severe Active, Chronic Plaque Psoriasis Who Have Failed on TNFα antaGoNists: A Clinical Trial EvalUating Treatment REsults

description: This study was designed to prove and quantify the hypothesis that secukinumab is effective, safe and well tolerated in the treatment of moderate to severe chronic plaque-type psoriasis in patients who are inadequate responders to anti-TNFα therapy in a United Kingdom (UK) and Republic of Ireland) specific population.
DOI: 10.5281/zenodo.17650401
title: Dataset of the article "Urban airborne allergenic pollen shows highly local patterns driven by public green spaces".

description: Raw nrITS2 metabarcoding reads used for analyses in this article
DOI: 10.13130/rd_unimi/6np0bt/9etxfq
title: Giugno_1894_Pagina_036.jpg

description: Bulletin of 1894/06/09
DOI: 10.13130/rd_unimi/cbrkhv/xi4rmp
title: Gennaio_1927_Pagina_068.jpg

description: Bulletin of 1927/01/17
DOI: 10.25934/pr00012340
title: Phase II Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Multiple-loading Dose Regimen Study to Assess the Safety, Efficacy and Duration of Response of AIN457 in Patients With Chronic Plaque-type Psoriasis.

description: Loading dose, four arm, double-blind, parallel group, placebo-controlled study comparing single and multiple doses of AIN457 to placebo in patients with a diagnosis of moderate to severe chronic plaque psoriasis.
DOI: 10.13130/rd_unimi/nsvbhr/kupwy2
title: Giugno_1890_Pagina_078.jpg

description: Bulletin of 1890/06/20
DOI: 10.13130/rd_unimi/v8alup/veb7rc
title: Giugno_1891_Pagina_075.jpg

description: Bulletin of 1891/06/19
DOI: 10.13130/rd_unimi/xu1sm0/iumdh7
title: Giugno_1893_Pagina_053.jpg

description: Bulletin of 1893/06/14
DOI: 10.25934/pr00012341
title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Exploratory Evaluation of Surrogate Markers of Cardiovascular Risk in Patients With Active Chronic Plaque-type Psoriasis Treated for up to 52 Weeks With Subcutaneous (s.c.) Secukinumab (300 mg or 150 mg).

description: The purpose of this study was to explore the effect of treatment with 300 mg or with 150 mg secukinumab (administered weekly for 4 weeks followed by four-weekly administration) on endothelial dysfunction and arterial stiffness after 12 weeks and for up to 52 weeks in subjects with chronic plaque-type psoriasis. Furthermore soluble biomarkers were assessed to evaluate the influence of secukinumab on cardiovascular risk. Magnetic resonance imaging (MRI) was performed in a sub-population to assess the treatment effect on arterial vessel wall morphometry in atherosclerosis prone vascular beds.
DOI: 10.25934/pr00012342
title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Secukinumab on Aortic Vascular Inflammation and Cardiometabolic Biomarkers After 12 Weeks of Treatment, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

description: This study evaluated the effect of secukinumab compared to placebo on aortic vascular inflammation in adult patients who have moderate to severe plaque psoriasis that is poorly controlled by current psoriasis treatments.
DOI: 10.13130/rd_unimi/awv4gb/buyzew
title: Giugno_1896_Pagina_031.jpg

description: Bulletin of 1896/06/08
DOI: 10.13130/rd_unimi/jvs9pt/ph813w
title: Giugno_1892_Pagina_051.jpg

description: Bulletin of 1892/06/13
DOI: 10.13130/rd_unimi/rjrjox/tnamku
title: Luglio_1895_Pagina_121.jpg

description: Bulletin of 1895/07/31
DOI: 10.25574/03205
title: Chandra X-ray Observatory ObsId 03205

description: DETAILED STUDY OF CLUSTER A907
DOI: 10.25934/pr00012343
title: A Multicenter, Randomized, Double-blind, Placebo-controlled, 52-weeks Study to Demonstrate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab Injections With 2 mL Pre-filled Syringes (300 mg) in Adult Subjects With Moderate to Severe Plaque Psoriasis

description: The aim of the study was to demonstrate efficacy, safety and tolerability of 2 mL pre-filled syringe of 300 mg secukinumab in treatment of moderate to severe plaque psoriasis.
DOI: 10.13130/rd_unimi/cbrkhv/2ccpfd
title: Gennaio_1927_Pagina_069.jpg

description: Bulletin of 1927/01/18
DOI: 10.13130/rd_unimi/gsbgp1/zfp2ky
title: Giugno_1889_Pagina_094.jpg

description: Bulletin of 1889/06/24
DOI: 10.13130/rd_unimi/v8alup/jenbfa
title: Giugno_1891_Pagina_076.jpg

description: Bulletin of 1891/06/19
DOI: 10.25934/pr00012344
title: A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab, to Demonstrate Efficacy After Twelve Weeks of Treatment and to Assess Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis With or Without Psoriatic Arthritis Comorbidity

description: The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis
DOI: 10.13130/rd_unimi/6np0bt/5wulul
title: Giugno_1894_Pagina_037.jpg

description: Bulletin of 1894/06/10
DOI: 10.13130/rd_unimi/jvs9pt/6etc8a
title: Giugno_1892_Pagina_052.jpg

description: Bulletin of 1892/06/13
DOI: 10.13130/rd_unimi/nsvbhr/tzkoj5
title: Giugno_1890_Pagina_079.jpg

description: Bulletin of 1890/06/20
DOI: 10.25574/03206
title: Chandra X-ray Observatory ObsId 03206

description: OVER-LUMINOUS ELLIPTICAL GALAXIES (AKA FOSSIL GROUPS)
DOI: 10.3886/e241288
title: The Impact of Early Investments in Urban School Systems in the United States

description: This is the replication package for "The Impact of Early Investments in Urban School Systems in the United States" by Ethan Schmick and Allison Shertzer. The Journal of Economic History. Forthcoming.
DOI: 10.13130/rd_unimi/awv4gb/dxlzka
title: Giugno_1896_Pagina_032.jpg

description: Bulletin of 1896/06/08